James L. Rubenstein
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
James L. Rubenstein has a total of 122 co-authors. Here are the top co-authors by number of shared publications:
Cigall Kadoch
Authors' Affiliations: Division of Hematology/Oncology, Genentech, South San Francisco; Helen Diller Comprehensive Cancer Center; and Department of Radiology, Laboratory Medicine, University of California, San Francisco, San Francisco, California
7 shared publicationsMarc A. Shuman
Division of Hematology/Oncology, University of California, San Francisco
7 shared publicationsPatrick Treseler
Department of Pathology, University of California, San Francisco, CA
6 shared publicationsLawrence D. Kaplan
Division of Hematology/Oncology, University of California, San Francisco (N.K.G., C.W., G.M., D.I.A., L.D.K., J.A.L., P.V., J.L.R.); Department of Pathology, University of California, San Francisco (A.N., P.A.T.); Department of Neurology, Memorial Sloan-Kettering Cancer Center, New York, NY (A.O.); Division of Hematology/Oncology, University of California, San Diego (E.G.R.); Division of Hematolo
4 shared publicationsLingjing Chen
Division of Hematology/Oncology, University of California, San Francisco
4 shared publicationsMichael McDermott
Authors' Affiliations: 1Division of Hematology/Oncology; 2Helen Diller Comprehensive Cancer Center; Departments of 3Radiology Neuroradiology Section, 4Neurological Surgery, and 5Pathology, University of California, San Francisco, California; 6Department of Haematology, Middlemore Hospital, Auckland, New Zealand; and 7Department of Ophthalmology, Scheie Eye Institute, University of Pennsylvania, Philadelphia, Pennsylvania
4 shared publications
Latest Publications
- 10 April 2017
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 58 (11) , 2748-2751
Regression of methotrexate-resistant AIDS-related primary central nervous system lymphoma with lenalidomide plus combination anti-retroviral therapy
A 33-year-old woman with a 2-year history of documented human immunodeficiency virus (HIV) infection presented to the emergency room at San Francisco General Hospital with a new-onset seizure disor...
- 10 April 2017
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 58 (11) , 2748-2751
Regression of methotrexate-resistant AIDS-related primary central nervous system lymphoma with lenalidomide plus combination anti-retroviral therapy
A 33-year-old woman with a 2-year history of documented human immunodeficiency virus (HIV) infection presented to the emergency room at San Francisco General Hospital with a new-onset seizure disor...
- 1 December 2016
- Published by Elsevier in Hematology/Oncology Clinics of North America
- Vol. 30 (6) , 1293-1316
The Challenge of Primary Central Nervous System Lymphoma
- 1 December 2016
- Published by Elsevier in Hematology/Oncology Clinics of North America
- Vol. 30 (6) , 1293-1316
The Challenge of Primary Central Nervous System Lymphoma
- Open Access
- 30 August 2016
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 19 (1) , 99-108
Long-term survival in AIDS-related primary central nervous system lymphoma
Background.: The optimal therapeutic approach for patients with AIDS-related primary central nervous system lymphoma (AR-PCNSL) remains undefined. While its incidence declined substantially with combination antiretroviral therapy (cART), AR-PCNSL remains a highly aggressive neoplasm for which whole brain radiotherapy (WBRT) is considered a standard first-line intervention.Methods.: To identify therapy-related factors associated with favorable survival, we first retrospectively analyzed outcomes of AR-PCNSL patients treated at San Francisco General Hospital, a public hospital with a long history of dedicated care for patients with HIV and AIDS-related malignancies. Results were validated in a retrospective, multicenter analysis that evaluated all newly diagnosed patients with AR-PCNSL treated with cART plus high-dose methotrexate (HD-MTX).Results.: We provide evidence that CD4+ reconstitution with cART administered during HD-MTX correlates with long-term survival among patients with CD4 <100. This was confirmed in a multicenter analysis which demonstrated that integration of cART regimens with HD-MTX was generally well tolerated and resulted in longer progression-free survival than other treatments. No profound differences in immunophenotype were identified in an analysis of AR-PCNSL tumors that arose in the pre- versus post-cART eras. However, we detected evidence for a demographic shift, as the proportion of minority patients with AR-PCNSL increased since advent of cART.Conclusion.: Long-term disease-free survival can be achieved in AR-PCNSL, even among those with histories of opportunistic infections, limited access to health care, and medical non-adherence. Given this, as well as the long-term toxicities of WBRT, we recommend that integration of cART plus first-line HD-MTX be considered for all patients with AR-PCNSL.
- 30 August 2016
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 19 (1) , 99-108
Open AccessLong-term survival in AIDS-related primary central nervous system lymphoma
Background.: The optimal therapeutic approach for patients with AIDS-related primary central nervous system lymphoma (AR-PCNSL) remains undefined. While its incidence declined substantially with combination antiretroviral therapy (cART), AR-PCNSL remains a highly aggressive neoplasm for which whole brain radiotherapy (WBRT) is considered a standard first-line intervention.Methods.: To identify therapy-related factors associated with favorable survival, we first retrospectively analyzed outcomes of AR-PCNSL patients treated at San Francisco General Hospital, a public hospital with a long history of dedicated care for patients with HIV and AIDS-related malignancies. Results were validated in a retrospective, multicenter analysis that evaluated all newly diagnosed patients with AR-PCNSL treated with cART plus high-dose methotrexate (HD-MTX).Results.: We provide evidence that CD4+ reconstitution with cART administered during HD-MTX correlates with long-term survival among patients with CD4 <100. This was confirmed in a multicenter analysis which demonstrated that integration of cART regimens with HD-MTX was generally well tolerated and resulted in longer progression-free survival than other treatments. No profound differences in immunophenotype were identified in an analysis of AR-PCNSL tumors that arose in the pre- versus post-cART eras. However, we detected evidence for a demographic shift, as the proportion of minority patients with AR-PCNSL increased since advent of cART.Conclusion.: Long-term disease-free survival can be achieved in AR-PCNSL, even among those with histories of opportunistic infections, limited access to health care, and medical non-adherence. Given this, as well as the long-term toxicities of WBRT, we recommend that integration of cART plus first-line HD-MTX be considered for all patients with AR-PCNSL.
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , 7502
Phase I investigation of lenalidomide plus rituximab and outcomes of lenalidomide maintenance in recurrent CNS lymphoma.
7502 Background: There is an unmet need for effective biological therapies for relapsed CNS lymphoma. Lenalidomide (CC-5013) is active in ABC-type DLBCL. We demonstrated activity of lenalidomide in preclinical models of refractory CNS DLBCL. These observations are the basis for this first trial of an IMiD monotherapy in CNS NHL, and in patients with inadequate responses to lenalidomide, with intravenous plus intraventricular rituximab. (NCT01542918). In an independent cohort, we evaluated lenalidomide maintenance after salvage in relapsed CNS NHL. Methods: The primary objective was to evaluate safety and efficacy of lenalidomide at 10, 20, 30 mg dose levels in refractory CD20+ CNS NHL. Secondary endpoints were to determine: CSF penetration of lenalidomide; feasibility of intraventricular plus intravenous rituximab; TTP of maintenance lenalidomide in an independent cohort of relapsed CNS NHL patients. Results: Thirteen subjects with refractory CNS DLBCL (8 PCNSL, 5 SCNSL; median age 63, range 46-78) were treated on the phase I protocol. 8 achieved > PR with lenalidomide monotherapy: 3 CR’s, 1 PR in brain parenchymal NHL; 2 CR of CSF NHL; 1 CR, 2 PR’s of intraocular NHL. Four maintained CR to lenalidomide > 9 months and two > 1.8 years. An independent cohort of 12 patients with recurrent CNS DLBCL (10 PCNSL, 2 SCNSL; median age 70, range 59-81) received lenalidomide monotherapy (5-10 mg) as maintenance after salvage. With median follow-up of > 18 months, TTP has been impressive: five maintained remissions > 2 years. Among 10 CNS DLBCL patients with multiple CNS relapses that received focal XRT or HD-MTX-rituximab salvage, followed by lenalidomide maintenance, TTP at CR 2-4 was >5 X longer than TTP in these patients after standard induction and consolidation chemotherapy, without lenalidomide. P<0.013; Hazard Ratio 3.75. Trough lenalidomide concentration in ventricular CSF was highest at 20 mg dose. Elevated CSF lactate predicted short PFS (p<0.01). Conclusions: Lenalidomide penetrates ventricular CSF and is active in relapsed CNS DLBCL. We provide the first evidence that maintenance lenalidomide significantly potentiates TTP after salvage in relapsed CNS DLBCL and delays WBRT. Clinical trial information: NCT01542918.
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , 7502
Phase I investigation of lenalidomide plus rituximab and outcomes of lenalidomide maintenance in recurrent CNS lymphoma.
7502 Background: There is an unmet need for effective biological therapies for relapsed CNS lymphoma. Lenalidomide (CC-5013) is active in ABC-type DLBCL. We demonstrated activity of lenalidomide in preclinical models of refractory CNS DLBCL. These observations are the basis for this first trial of an IMiD monotherapy in CNS NHL, and in patients with inadequate responses to lenalidomide, with intravenous plus intraventricular rituximab. (NCT01542918). In an independent cohort, we evaluated lenalidomide maintenance after salvage in relapsed CNS NHL. Methods: The primary objective was to evaluate safety and efficacy of lenalidomide at 10, 20, 30 mg dose levels in refractory CD20+ CNS NHL. Secondary endpoints were to determine: CSF penetration of lenalidomide; feasibility of intraventricular plus intravenous rituximab; TTP of maintenance lenalidomide in an independent cohort of relapsed CNS NHL patients. Results: Thirteen subjects with refractory CNS DLBCL (8 PCNSL, 5 SCNSL; median age 63, range 46-78) were treated on the phase I protocol. 8 achieved > PR with lenalidomide monotherapy: 3 CR’s, 1 PR in brain parenchymal NHL; 2 CR of CSF NHL; 1 CR, 2 PR’s of intraocular NHL. Four maintained CR to lenalidomide > 9 months and two > 1.8 years. An independent cohort of 12 patients with recurrent CNS DLBCL (10 PCNSL, 2 SCNSL; median age 70, range 59-81) received lenalidomide monotherapy (5-10 mg) as maintenance after salvage. With median follow-up of > 18 months, TTP has been impressive: five maintained remissions > 2 years. Among 10 CNS DLBCL patients with multiple CNS relapses that received focal XRT or HD-MTX-rituximab salvage, followed by lenalidomide maintenance, TTP at CR 2-4 was >5 X longer than TTP in these patients after standard induction and consolidation chemotherapy, without lenalidomide. P<0.013; Hazard Ratio 3.75. Trough lenalidomide concentration in ventricular CSF was highest at 20 mg dose. Elevated CSF lactate predicted short PFS (p<0.01). Conclusions: Lenalidomide penetrates ventricular CSF and is active in relapsed CNS DLBCL. We provide the first evidence that maintenance lenalidomide significantly potentiates TTP after salvage in relapsed CNS DLBCL and delays WBRT. Clinical trial information: NCT01542918.
- Open Access
- 1 March 2015
- Vol. 4 (1) , 11
New approaches in primary central nervous system lymphoma
New approaches in primary central nervous system lymphoma
- 1 March 2015
- Vol. 4 (1) , 11
Open AccessNew approaches in primary central nervous system lymphoma
New approaches in primary central nervous system lymphoma
- Open Access
- 16 May 2014
- Published by Wiley in British Journal of Haematology
- Vol. 166 (3) , 311-325
Progress in central nervous system lymphomas
Summary: Until recently, primary central nervous system lymphoma (PCNSL) was associated with a uniformly dismal prognosis. It is now reasonable to anticipate long‐term survival and possibly cure for a significant proportion of patients diagnosed with PCNSL. Accumulated data generated over the past 10 years has provided evidence that long‐term progression‐free survival (PFS) can reproducibly be attained in a significant fraction of PCNSL patients that receive dose‐intensive chemotherapy consolidation, without whole brain radiotherapy. One consolidative regimen that has reproducibly demonstrated promise is the combination of infusional etoposide plus high‐dose cytarabine (EA), administered in first complete remission after methotrexate, temozolomide and rituximab‐based induction. Given evolving principles of management and the mounting evidence for reproducible improvements in survival rates in prospective clinical series, our goal in this review is to highlight and update principles in diagnosis, staging and management as well as to review data regarding the pathogenesis of central nervous system lymphomas, information that is likely to constitute a basis for the implementation of novel therapies that are requisite for further progress in this unique phenotype of non‐Hodgkin lymphoma.
- 16 May 2014
- Published by Wiley in British Journal of Haematology
- Vol. 166 (3) , 311-325
Open AccessProgress in central nervous system lymphomas
Summary: Until recently, primary central nervous system lymphoma (PCNSL) was associated with a uniformly dismal prognosis. It is now reasonable to anticipate long‐term survival and possibly cure for a significant proportion of patients diagnosed with PCNSL. Accumulated data generated over the past 10 years has provided evidence that long‐term progression‐free survival (PFS) can reproducibly be attained in a significant fraction of PCNSL patients that receive dose‐intensive chemotherapy consolidation, without whole brain radiotherapy. One consolidative regimen that has reproducibly demonstrated promise is the combination of infusional etoposide plus high‐dose cytarabine (EA), administered in first complete remission after methotrexate, temozolomide and rituximab‐based induction. Given evolving principles of management and the mounting evidence for reproducible improvements in survival rates in prospective clinical series, our goal in this review is to highlight and update principles in diagnosis, staging and management as well as to review data regarding the pathogenesis of central nervous system lymphomas, information that is likely to constitute a basis for the implementation of novel therapies that are requisite for further progress in this unique phenotype of non‐Hodgkin lymphoma.
- 10 March 2014
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 32 (8) , 858-859
Reply to M.C. Chamberlain
- 10 March 2014
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 32 (8) , 858-859
Reply to M.C. Chamberlain
- 15 February 2014
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 20 (4) , 1029-1041
Complement Activation and Intraventricular Rituximab Distribution in Recurrent Central Nervous System Lymphoma
Purpose: To elucidate the mechanistic basis for efficacy of intrathecal rituximab. We evaluated complement activation as well as the pharmacokinetics of intraventricular rituximab in patients who participated in two phase 1 multicenter studies. Experimental Design: We evaluated complement activation as a candidate mediator of rituximab within the central nervous system (CNS). Complement C3 and C5b-9 were quantified by ELISA in serial cerebrospinal fluid (CSF) specimens after intraventricular rituximab administration. We determined rituximab concentration profiles in CSF and serum. A population three- compartment pharmacokinetic model was built to describe the disposition of rituximab following intraventricular administration. The model was derived from results of the first trial and validated with results of the second trial. Results: Complement C3 and C5b-9 were reproducibly activated in CSF after intraventricular rituximab. Ectopic expression of C3 mRNA and protein within CNS lymphoma lesions was localized to myeloid cells. Constitutive high C3 activation at baseline was associated with adverse prognosis. A pharmacokinetic model was built, which contains three distinct compartments, to describe the distribution of rituximab within the neuroaxis after intraventricular administration. Conclusions: We provide the first evidence of C3 activation within the neuroaxis with intraventricular immunotherapy and suggest that complement may contribute to immunotherapeutic responses of rituximab in CNS lymphoma. Penetration of rituximab into neural tissue is supported by this pharmacokinetic model and may contribute to efficacy. These findings have general implications for intraventricular immunotherapy. Our data highlight potential innovations to improve efficacy of intraventricular immunotherapy both via modulation of the innate immune response as well as innovations in drug delivery. Clin Cancer Res; 20(4); 1029–41. ©2013 AACR.
- 15 February 2014
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 20 (4) , 1029-1041
Complement Activation and Intraventricular Rituximab Distribution in Recurrent Central Nervous System Lymphoma
Purpose: To elucidate the mechanistic basis for efficacy of intrathecal rituximab. We evaluated complement activation as well as the pharmacokinetics of intraventricular rituximab in patients who participated in two phase 1 multicenter studies. Experimental Design: We evaluated complement activation as a candidate mediator of rituximab within the central nervous system (CNS). Complement C3 and C5b-9 were quantified by ELISA in serial cerebrospinal fluid (CSF) specimens after intraventricular rituximab administration. We determined rituximab concentration profiles in CSF and serum. A population three- compartment pharmacokinetic model was built to describe the disposition of rituximab following intraventricular administration. The model was derived from results of the first trial and validated with results of the second trial. Results: Complement C3 and C5b-9 were reproducibly activated in CSF after intraventricular rituximab. Ectopic expression of C3 mRNA and protein within CNS lymphoma lesions was localized to myeloid cells. Constitutive high C3 activation at baseline was associated with adverse prognosis. A pharmacokinetic model was built, which contains three distinct compartments, to describe the distribution of rituximab within the neuroaxis after intraventricular administration. Conclusions: We provide the first evidence of C3 activation within the neuroaxis with intraventricular immunotherapy and suggest that complement may contribute to immunotherapeutic responses of rituximab in CNS lymphoma. Penetration of rituximab into neural tissue is supported by this pharmacokinetic model and may contribute to efficacy. These findings have general implications for intraventricular immunotherapy. Our data highlight potential innovations to improve efficacy of intraventricular immunotherapy both via modulation of the innate immune response as well as innovations in drug delivery. Clin Cancer Res; 20(4); 1029–41. ©2013 AACR.
- 8 January 2014
- Published by Springer Nature
- p. 207-223
CNS Lymphoma
- Open Access
- 20 November 2013
- Published by Elsevier in Annals of Oncology
- Vol. 25 (2) , 316-322
Beyond high-dose methotrexate and brain radiotherapy: novel targets and agents for primary CNS lymphoma
While there has been significant progress in outcomes for patients diagnosed with primary central nervous system (CNS) lymphoma (PCNSL), survival rates will likely plateau with the current armamentarium of agents used to treat these patients. Moreover, given that PCNSL increasingly impacts an older population, a significant proportion of patients are not eligible for intensive therapies such as high-dose chemotherapy or whole-brain radiation. There is a need for the development of novel agents, which target key survival pathways in order to continue to make progress in this disease. We reviewed the key molecular pathways and genomic aberrations in PCNSL in order to identify candidate targets. We focused on molecules and pathways that have been identified and confirmed by more than one investigator or methodology. While PCNSL tumors usually express a BCL6+, MUM1+ ‘activated, germinal center’ immunophenotype, they exhibit multiple shared genetic properties with ABC-type diffuse large B-cell lymphomas. Candidate targets and pathways include NFkB, the B-cell receptor, the JAK/STAT pathway, IRF4, BCL-6 as well as PIM kinases. Elements of the tumor microenvironment that may be exploited therapeutically include chemokine pathways, as well as macrophage and T-cell responses. There is a significant need for developing novel therapies in PCNSL, given that an increasing proportion of patients are not eligible for high-dose chemotherapy and brain radiation is associated with detrimental cognitive side-effects. We provide an overview of potential drug targets and novel agents that may be integrated with existing strategies in order to make further progress in this disease.
- 20 November 2013
- Published by Elsevier in Annals of Oncology
- Vol. 25 (2) , 316-322
Open AccessBeyond high-dose methotrexate and brain radiotherapy: novel targets and agents for primary CNS lymphoma
While there has been significant progress in outcomes for patients diagnosed with primary central nervous system (CNS) lymphoma (PCNSL), survival rates will likely plateau with the current armamentarium of agents used to treat these patients. Moreover, given that PCNSL increasingly impacts an older population, a significant proportion of patients are not eligible for intensive therapies such as high-dose chemotherapy or whole-brain radiation. There is a need for the development of novel agents, which target key survival pathways in order to continue to make progress in this disease. We reviewed the key molecular pathways and genomic aberrations in PCNSL in order to identify candidate targets. We focused on molecules and pathways that have been identified and confirmed by more than one investigator or methodology. While PCNSL tumors usually express a BCL6+, MUM1+ ‘activated, germinal center’ immunophenotype, they exhibit multiple shared genetic properties with ABC-type diffuse large B-cell lymphomas. Candidate targets and pathways include NFkB, the B-cell receptor, the JAK/STAT pathway, IRF4, BCL-6 as well as PIM kinases. Elements of the tumor microenvironment that may be exploited therapeutically include chemokine pathways, as well as macrophage and T-cell responses. There is a significant need for developing novel therapies in PCNSL, given that an increasing proportion of patients are not eligible for high-dose chemotherapy and brain radiation is associated with detrimental cognitive side-effects. We provide an overview of potential drug targets and novel agents that may be integrated with existing strategies in order to make further progress in this disease.